Abstract: The invention is related to gel preparations capable of absorbing as well as releasing liquid, and the use of such gel preparations in the treatment of wounds.
Type:
Application
Filed:
October 18, 2013
Publication date:
May 22, 2014
Applicant:
Euro-Celtique S.A.
Inventors:
Sabine SCHERER, Chirstian Wagner, Christian Leuner, Wolfgang Fleischer
Abstract: Tramadol or a pharmaceutically acceptable salt thereof is used in the manufacture of a pharmaceutical preparation for the treatment of functional gastrointestinal disorders such as irritable bowel syndrome.
Abstract: Benzomorphan compounds are found to be useful for treating, ameliorating or preventing pruritus, and in particular pruritus associated with (including induced by) the administration of opioids. Antipruritic activity is believed to be mediated through the dual action of the compounds as mu opioid receptor antagonists and kappa opioid receptor agonists. Pharmaceutical compositions contain therapeutically effective amounts of these useful compounds, optionally in combination with second therapeutic agents, such as opioid or non-opioid analgesics or other compounds.
Abstract: The present invention relates to an opioid controlled release oral dosage form comprising at least one opioid for the manufacture of a medicament to treat patients with Chronic Obstructive Pulmonary Disease (COPD).
Type:
Application
Filed:
July 19, 2013
Publication date:
February 27, 2014
Applicant:
Euro-Celtique S.A.
Inventors:
Wolfgang FLEISCHER, Karen REIMER, Petra LEYENDECKER
Abstract: The invention concerns a storage stable pharmaceutical formulation comprising preferably two active compounds in a non-swellable diffusion matrix, whereby the compounds are released from the matrix in a sustained, invariant and, if several compounds are present, independent manner and the matrix is determined with respect to its substantial release characteristics by ethylcellulose and at least one fatty alcohol. The invention also concerns methods for producing such pharmaceutical formulations.
Abstract: The present invention provides a pharmaceutical dosage form comprising an opioid agonist and an opioid antagonist for use in the treatment of Parkinson's disease. The present invention also refers to the use of an opioid agonist and an opioid antagonist in such a dosage form.
Abstract: The present invention concerns a dosage form comprising oxycodone and naloxone which is characterized by specific in vivo parameters such as tmax, Cmax, AUCt value, mean bowel function score and/or duration of analgesic efficacy.
Type:
Application
Filed:
October 2, 2013
Publication date:
January 30, 2014
Applicant:
Euro-Celtique S.A.
Inventors:
Petra LEYENDECKER, Michael Hopp, Kevin Smith
Abstract: The invention concerns a method for the production of a pharmaceutical preparation for the treatment of Herpes forms that is characterized in, that the preparation comprises at least one antiseptic compound associated with a particular carrier.
Abstract: The present invention provides a dosage form, particularly a tamper resistant dosage form, comprising; non-stretched melt extruded particulates comprising a drug selected from an opioid agonist, a tranquilizer, a CNS depressant, a CNS stimulant or a sedative hypnotic; and a matrix; wherein said melt extruded particulates are present as a discontinuous phase in said matrix.
Abstract: According to the present invention there is provided a pharmaceutical product for retention in the stomach. The product is produced by extrusion. The use of extrusion enables the product to take many useful forms. The product may comprise a sheet of hydratable polymer, the hydrated sheet being of a size which will not pass out of the stomach, for example a shaped sheet or a roll. The product may also comprise a scaled hollow tubular extrudate, for example a tube scaled at both ends. The product may comprise a filled capsule.
Abstract: The present invention relates to an opioid controlled release oral dosage form comprising at least one opioid for the manufacture of a medicament to treat patients with Chronic Obstructive Pulmonary Disease (COPD).
Type:
Grant
Filed:
June 8, 2005
Date of Patent:
August 27, 2013
Assignee:
Euro-Celtique S.A.
Inventors:
Wolfgang Fleischer, Karen Reimer, Petra Leyendecker
Abstract: A solid, oral controlled release pharmaceutical dosage form has a water-soluble active ingredient dispersed in a matrix and releases the active ingredient at such a rate upon administration that the median tmax is 2.5 to 6 hours and the ratio of mean Cmax to mean plasma level of the active ingredient at 24 hours is in the range of 1.5 to 3.5.
Type:
Grant
Filed:
December 18, 2006
Date of Patent:
August 13, 2013
Assignee:
Euro-Celtique S.A.
Inventors:
Ronald Brown Miller, Stewart Thomas Leslie, Sandra Therese Antoinette Malkowska, Derek Allan Prater, Trevor John Knott, Hassan Mohammad
Abstract: The present invention relates to prolonged release pharmaceutical dosage forms, the manufacture thereof as well as their use for administration to human being
Abstract: The present invention relates to prolonged release pharmaceutical dosage forms, the manufacture thereof as well as their use for administration to human beings.
Type:
Application
Filed:
May 10, 2011
Publication date:
July 11, 2013
Applicant:
Euro-Celtique S.A.
Inventors:
Helen Kathleen Danagher, Hassan Mohammad, Malcolm Walden, Geoffrey Gerard Hayes, Jonathon Oliver Whitehouse, Thinnayam Naganathan Krishnamurthy, Ricardo Alberto Vargas Rincon
Abstract: The invention is related to gel preparations capable of absorbing as well as releasing liquid, and the use of such gel preparations in the treatment of wounds.
Abstract: The present invention is directed to a storage stable package of a iodophor containing particulate pharmaceutically acceptable carrier compositions. The invention is particularly directed to a storage stable package of a PVP-iodine liposome compositions. The packaging material is generally plastic, paper or cardboard.
Abstract: The present invention relates to pharmaceutical compositions of the neuroactive steroid 3?-hydroxy-3?-methoxymethyl-21-(1?-imidazolyl)-5?-pregnan-20-one or a pharmaceutically-acceptable salt or solvate thereof, with properties desirable for use in treating mood disorders and the like. The pharmaceutical compositions provide sustained therapeutic plasma levels of 3?-hydroxy-3?-methoxymethyl-21-(1?-imidazolyl)-5?-pregnan-20-one. The present invention also relates to methods of treating these disorders by administering the pharmaceutical compositions.
Abstract: Pharmaceutical compositions and dosage forms comprising an adsorbent, and an adverse agent, such as an opioid antagonist. In one embodiment, at least a portion of the adverse agent is on the surface or within the micropore structure of an adsorbent material. The pharmaceutical compositions and dosage forms comprising the adsorbent and the adverse agent are useful for preventing or discouraging tampering, abuse, misuse or diversion of a dosage form containing an active pharmaceutical agent, such as an opioid. The present invention also relates to methods for treating a patient with such a dosage form, as well as kits containing such a dosage form with instructions for using the dosage form to treat a patient. The present invention further relates to process for preparing such pharmaceutical compositions and dosage forms.